Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Ruxolitinib
Sponsors: University of California, San Francisco; Incyte Pharmaceuticals
Not yet recruiting - verified May 2017
from #ORL via a.lsfakia on Inoreader http://ift.tt/2qlaDm3
via IFTTT
http://ift.tt/2qlyKRy
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 8 April 2017 Source: European Journal of Vascular and Endovascular Surgery Author(s): J.P. Archie ...
-
The Angle Orthodontist, Ahead of Print. http://ift.tt/2hE4ZYJ http://ift.tt/2hCj3k2
-
Related Articles Oleogustus: The Unique Taste of Fat. Chem Senses. 2015 Sep;40(7):507-16 Authors: Running CA, Craig BA, Mattes RD A...
-
Abstract Background Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-for...
-
Abstract Introduction Bruton tyrosine kinase (BTK) is a key component of B-cell receptor signalling, critical for cell proliferation. Ac...
-
A novel potassium oxalate-based hydrogel is proposed for treating dentin hypersensitivity and this study evaluates its in vitro performance...
-
Abstract Background Preoperative nutritional status is considered to affect the short-term and long-term outcomes of cancer patients. Th...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου